New hope against Alzheimer’s: Viagra-like drug shows promising results in study
An experimental drug, similar to Viagra, has shown promising results in slowing the decline of memory and cognitive abilities in people in the early stages of Alzheimer’s.
A new international study has brought hope for the treatment of Alzheimer’s disease. The experimental drug AR1001, developed by the South Korean company AriBio, has shown that it may slow the progression of the disease.
In the phase 3 clinical trial, which involved 1,535 people from 13 countries, the drug slowed the decline in cognitive abilities by 31 percent over one year in the group of 604 patients who were not taking other Alzheimer’s medications.
AR1001 belongs to the same family of drugs as Viagra and works by affecting the widening of blood vessels and blood circulation, including in the brain.
However, the results were not the same for all participants.
In the overall analysis of the study, including people who were receiving other treatments for Alzheimer’s, a statistically significant benefit could not be demonstrated.
Researchers consider the results promising, but emphasize that further analyses are needed to understand the long-term effects and determine whether the drug can be approved for use.
AR1001 is not yet available to the public and should not be confused with Viagra.
Experts warn that using Viagra to treat Alzheimer’s is not recommended.















